PDF(2108 KB)
Value of ginsenoside Rb1 in alleviating coronary artery lesion in a mouse model of Kawasaki disease
QI Shuang-Hui, XIAO Feng, WEI Bing, QIN Can
Chinese Journal of Contemporary Pediatrics ›› 2020, Vol. 22 ›› Issue (9) : 1034-1040.
PDF(2108 KB)
PDF(2108 KB)
Value of ginsenoside Rb1 in alleviating coronary artery lesion in a mouse model of Kawasaki disease
Objective To study the effect and related signaling pathways of ginsenoside Rb1 in the treatment of coronary artery lesion (CAL) in a mouse model of Kawasaki disease (KD). Methods BALB/c mice were randomly divided into a control group, a model group, an aspirin group, a low-dose ginsenoside Rb1 group (50 mg/kg), and a high-dose ginsenoside Rb1 group (100 mg/kg), with 12 mice in each group. All mice except those in the control group were given intermittent intraperitoneal injection of 10% bovine serum albumin to establish a mouse model of KD. The mice in the aspirin group, the low-dose ginsenoside Rb1 group, and the high-dose ginsenoside Rb1 group were given the corresponding drug by gavage for 20 days after modeling. Hematoxylin and eosin staining was used to observe the pathological changes of coronary artery tissue. ELISA was used to measure the levels of the inflammatory cytokines tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and interleukin-1β (IL-1β) in serum and coronary artery tissue. Western blot was used to measure the relative expression levels of proteins involved in the regulation of the AMPK/mTOR autophagy signaling pathway and the PI3K/Akt oxidative stress signaling pathway in coronary artery tissue. Results The observation of pathological sections showed that compared with the model group, the high-dose ginsenoside Rb1 group had significant improvement in the symptoms of vascular wall thickening, intimal edema, fiber rupture, and inflammatory infiltration of endothelial cells. Compared with the control group, the model and low-dose ginsenoside Rb1 groups had significant increases in the levels of TNF-α, IL-6, and IL-1β in serum and coronary artery tissue (P < 0.05); the model group had significant increases in the expression levels of P-AMPK/AMPK, P-mTOR/mTOR, and P-P70S6/P70S6 in coronary artery tissue (P < 0.05) and significant reductions in the expression levels of P-PI3K/PI3K, P-AKT/AKT, and P-GSK-3β/GSK-3β in coronary artery tissue (P < 0.05). Compared with the model group, the aspirin group and the high-dose ginsenoside Rb1 group had significant reductions in the levels of TNF-α, IL-6, and IL-1β (P < 0.05); the low- and high-dose ginsenoside Rb1 groups had significant reductions in the expression levels of P-AMPK/AMPK, P-mTOR/mTOR, and P-P70S6/P70S6 (P < 0.05) in a dose-dependent manner between the two groups (P < 0.05); the low-dose ginsenoside Rb1 group had no significant change in the expression level of P-PI3K/PI3K (P > 0.05) and had significant increases in the expression levels of P-AKT/AKT and P-GSK-3β/GSK-3β (P < 0.05), while the high-dose ginsenoside Rb1 group had significant increases in the relative protein expression levels of the above three proteins (P < 0.05). Compared with the low-dose ginsenoside Rb1 group, the aspirin group and the high-dose ginsenoside Rb1 group had significant reductions in the levels of TNF-α, IL-6, and IL-1β (P < 0.05); the high-dose ginsenoside Rb1 group had significant increases in the expression levels of P-PI3K/PI3K and P-AKT/AKT (P < 0.05). Conclusions Ginsenoside Rb1 can effectively alleviate CAL in a mouse model of KD in a dose-dependent manner, possibly by regulating the AMPK/mTOR/P70S6 autophagy signaling pathway to inhibit CAL inflammation and regulating the PI3K/AKT/GSK-3β oxidative stress signaling pathway to exert a biological activity of protection against coronary artery endothelial cell injury.
Ginsenoside Rb1 / Kawasaki disease / Coronary artery lesion / Anti-inflammation / Signaling pathway / Mice
[1] 李焰, 王献民, 柳颐龄, 等. 川崎病患儿并发冠状动脉病变的危险因素分析[J]. 中国当代儿科杂志, 2012, 14(12):938-941.
[2] 胡景伟, 杨凌, 郑承宁, 等. 川崎病并发冠状动脉病变的临床特点[J]. 中国当代儿科杂志, 2010, 12(3):228-230.
[3] 张倩, 项如莲. 静脉注射丙种球蛋白无反应型川崎病的诊治进展[J]. 中国当代儿科杂志, 2009, 11(4):318-321.
[4] 徐明国, 门丽娜, 祖莹, 等. 人血丙种球蛋白和阿司匹林治疗对川崎病患儿循环内皮祖细胞功能的影响[J]. 中国当代儿科杂志, 2011, 13(12):966-969.
[5] 解玉. 川崎病冠状动脉病变与内皮功能障碍[J]. 中国当代儿科杂志, 2003, 5(2):177-179.
[6] 邓永超, 王勋, 唐喜春, 等. 儿童川崎病并发冠状动脉损害的危险因素分析[J]. 中国当代儿科杂志, 2015, 17(9):927-931.
[7] 陈婧, 马彬, 林丽星, 等. 不同剂量丙种球蛋白治疗川崎病的疗效的Meta分析[J]. 中国当代儿科杂志, 2011, 13(8):638-643.
[8] 刘舒, 吕金晓, 郑蓓诗, 等. 人参皂苷Rb1改善术后疲劳综合征大鼠中枢炎症反应的机制研究[J]. 中草药, 2015, 46(14):2104-2110.
[9] 周彬, 吴琳, 凌叶盛, 等. 人参皂苷Rb1通过抑制NF-κB p65介导的炎症和氧化应激改善内皮细胞复制性衰老[J]. 中山大学学报(医学科学版), 2018, 39(6):835-843.
[10] 李江津, 刘正湘. 人参皂苷Rb1对缺氧复氧诱导内皮细胞凋亡的影响[J]. 临床心血管病杂志, 2005, 21(12):728-730.
[11] 柯世业, 石光耀, 刘定辉, 等. 人参皂苷Rb1通过Sirt3/SOD2通路延缓高糖诱导的人脐静脉内皮细胞衰老[J]. 中山大学学报(医学科学版), 2019, 40(3):329-336.
[12] 邹悦, 康乃馨, 王彦儿, 等. 人参皂苷Rb1对川崎病小鼠治疗作用的研究[J]. 中医药学报, 2017, 45(6):40-44.
[13] Rowley AH, Shulman ST. Pathogenesis and management of Kawasaki disease[J]. Expert Rev Anti Infect Ther, 2010, 8(2):197-203.
[14] Qing L, Fu J, Wu P, et al. Metformin induces the M2 macrophage polarization to accelerate the wound healing via regulating AMPK/mTOR/NLRP3 inflammasome singling pathway[J]. Am J Transl Res, 2019, 11(2):655-668.
[15] Doble BW, Woodgett JR. GSK-3:tricks of the trade for a multi-tasking kinase[J]. J Cell Sci, 2003, 116(Pt 7):1175-1186.
[16] Kaytor MD, Orr HT. The GSK3 beta signaling cascade and neurodegenerative disease[J]. Curr Opin Neurobiol, 2002, 12(3):275-278.
[17] 杨述亮, 韩燕, 李占清. PI3K/AKT/GSK-3β信号通路与心肌缺血/再灌注损伤的相关性研究[J]. 医学综述, 2015, 21(9):1571-1574.
[18] 韦卫中, 陈绍军, 王宏伟. 免疫性血管炎致冠状动脉扩张的实验研究[J]. 中华儿科杂志, 2003, 41(3):227-228.
[19] An X, Lv H, Tian J, et al. Role of the PTEN/PI3K/VEGF pathway in the development of Kawasaki disease[J]. Exp Ther Med, 2016, 11(4):1318-1322.
[20] Onouchi Z, Ikuta K, Nagamatsu K, et al. Coronary artery aneurysms develop in weanling rabbits with serum sickness but not in mature rabbits. An experimental model for Kawasaki disease in humans[J]. Angiology, 1995, 46(8):679-687.
[21] 何云, 魏钰书, 杨锡强. 川崎病的动物模型及其发病机制研究进展[J]. 国际儿科学杂志, 2007, 34(1):64-66.
[22] 田鑫, 贺湘玲, 方亦兵. 川崎病冠状动脉炎的动物模型研究进展[J]. 医学临床研究, 2008, 25(1):112-115.
[23] 田鑫, 贺湘玲, 方亦兵, 等. 血小板及其调控因子在幼兔免疫性血管炎中的动态变化[J]. 中国当代儿科杂志, 2009, 11(10):850-853.
[24] 田鑫, 贺湘玲, 方亦兵, 等. 血小板与血小板生成素及转化生长因子β1在川崎病动物模型中的变化及意义[J]. 广东医学, 2010, 31(1):32-35.
[25] 张新艳, 何婷, 凌加云, 等. 川崎病患儿急性期IL-38和IL-1β水平及其临床意义[J]. 中国当代儿科杂志, 2018, 20(7):543-548.
[26] 孙瑞丽, 朱淑霞, 张燕燕, 等. 川崎病患儿急性期外周血Th9细胞与细胞因子IL-9的变化及临床意义[J]. 中国当代儿科杂志, 2016, 18(8):721-725.
[27] Barranco C. Vasculitis syndromes:Kawasaki disease is IL-1β-mediated[J]. Nat Rev Rheumatol, 2016, 12(12):693.
[28] Lee Y, Wakita D, Dagvadorj J, et al. IL-1 signaling is critically required in stromal cells in Kawasaki disease vasculitis mouse model:role of both IL-1α and IL-1β[J]. Arterioscler Thromb Vasc Biol, 2015, 35(12):2605-2616.
[29] Alphonse MP, Duong TT, Shumitzu C, et al. Inositol-triphosphate 3-kinase C mediates inflammasome activation and treatment response in Kawasaki disease[J]. J Immunol, 2016, 197(9):3481-3489.
[30] Deretic V, Klionsky DJ. Autophagy and inflammation:a special review issue[J]. Autophagy, 2018, 14(2):179-180.
[31] Ni N, Liu Q, Ren H, et al. Ginsenoside Rb1 protects rat neural progenitor cells against oxidative injury[J]. Molecules, 2014, 19(3):3012-3024.
[32] 段超, 杜忠东, 王玉, 等. 川崎病冠脉瘤患儿远期血管内皮功能的研究[J]. 中国当代儿科杂志, 2011, 13(5):373-376.
[33] 柳颐龄, 王献民, 李焰, 等. 内源性血管弹性蛋白酶在川崎病冠状动脉重构中的作用研究[J]. 中国当代儿科杂志, 2014, 16(4):389-392.
[34] Shan H, Zhang S, Wei X, et al. Protection of endothelial cells against Ang Ⅱ-induced impairment:involvement of both PPARα and PPARγ via PI3K/Akt pathway[J]. Clin Exp Hypertens, 2016, 38(7):571-577.
[35] Xia G, Fan F, Liu M, et al. Aldehyde dehydrogenase 2 deficiency blunts compensatory cardiac hypertrophy through modulating Akt phosphorylation early after transverse aorta constriction in mice[J]. Biochim Biophys Acta, 2016, 1862(9):1587-1593.
